Allen Human Brain Atlas is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Allen Human Brain Atlas is a comprehensive map of gene expression across the adult human brain, produced by the Allen Institute for Brain Science. Launched in 2010, it provides the first complete transcriptome atlas of the human brain, representing a fundamental resource for understanding brain function in health and disease [1]. This landmark dataset has transformed our understanding of regional and cellular gene expression patterns in the human brain, providing an essential reference for neuroscience research across multiple domains [2].
The Allen Human Brain Atlas emerged from the success of the Allen Mouse Brain Atlas, extending the systematic gene expression mapping approach to the human brain. This project required unprecedented coordination of brain banking, tissue processing, and molecular analysis [3].
- 2008 - Project conception and planning
- 2010 - Initial data release with microarray data
- 2012 - Complete atlas publication in Nature [2]
- 2015 - Aging brain transcriptome added
- 2020 - Integration with SEA-AD (Seattle Alzheimer's Disease Brain Cell Atlas) project [4]
- 2022 - Single-nucleus RNA sequencing data integration
The atlas contains comprehensive gene expression data:
- Genome-wide coverage - All protein-coding genes (~20,000 genes)
- Multiple donors - Six anatomically characterized adult human brains
- Complete brain coverage - 17 major brain regions sampled
- Multiple platforms - Both microarray and RNA-seq data
Detailed spatial localization of gene expression across all major brain regions:
- Cerebral cortex - All cortical lobes (frontal, parietal, temporal, occipital) with layer-specific sampling
- Subcortical structures - Thalamus, hypothalamus, basal ganglia, hippocampus
- Cerebellum - Distinct transcriptional profile from cerebrum
- Brainstem - Midbrain, pons, medulla including substantia nigra
Individual donor profiles enable rigorous analysis:
- Clinical characterization - Comprehensive medical history
- Neuropathological assessment - Absence of neurodegenerative disease pathology
- Demographic data - Age, sex, ethnicity (balanced sampling)
- Quality metrics - RNA integrity (RIN scores > 7), tissue quality
Brain tissue was systematically sampled using standardized protocols:
- Rapid autopsy - Postmortem intervals < 24 hours to minimize RNA degradation
- Detailed dissection - Precise regional localization using stereotaxic coordinates
- Cryopreservation - Maintained RNA integrity throughout processing
- Quality control - Rigorous QC standards including RNA integrity number (RIN) validation
Multiple complementary technologies were employed:
| Technology |
Samples |
Information |
| Microarray |
3,700+ |
Genome-wide expression profiling |
| RNA-seq |
1,200+ |
High-resolution transcriptome |
| ISH |
1,000+ genes |
Cellular-level spatial expression patterns |
| Single-nucleus RNA-seq |
80,000+ |
Nuclear transcriptomes from frozen tissue |
The Human Brain Atlas is critical for understanding human brain diseases [5]:
The atlas enables researchers to understand:
- Regional vulnerability - Why specific regions like entorhinal cortex and hippocampus are affected first in Alzheimer's disease
- Gene expression changes - Transcriptional alterations in disease-vulnerable regions
- Cell type specificity - Which neurons and glia express disease-associated genes like APP, APOE, and TREM2
- Comparative analysis - Normal vs. disease expression patterns
- Amyloid and tau pathology - Regional distribution patterns of protein aggregates [6]
The atlas provides unique insights into Parkinson's disease:
- Dopaminergic system - Substantia nigra expression patterns reveal vulnerability of dopaminergic neurons
- Lewy body pathology - Regional distribution of alpha-synuclein aggregation
- Protein networks - Affected pathways in PD pathogenesis
- Neuroprotective factors - Expression of BDNF and other trophic factors [7]
The atlas supports ALS research through:
- Motor cortex involvement - Upper motor neuron expression profiles
- Spinal cord - Lower motor neuron transcriptomes
- Non-motor regions - Frontal cortex involvement in ALS-FTD spectrum
- Glial contributions - Astrocyte and microglia gene expression [8]
Understanding FTD through:
- Regional specificity - Frontal and temporal cortex vulnerability
- TDP-43 pathology - Protein aggregation patterns
- Genetic risk factors - MAPT, GRN, and C9orf72 expression
The web-based interface provides comprehensive access:
- Gene search - Find expression for any gene across the brain
- Region comparison - Compare expression across brain regions
- 3D visualization - Interactive brain exploration
- RNA-seq viewer - Transcriptome data browsing
- Differential expression - Compare normal vs. disease states
URL: https://human.brain-map.org/
Researchers can access downloadable datasets:
- Expression matrices - Raw and normalized expression data
- Sample metadata - Complete donor and tissue information
- Processed data - Quality-controlled datasets ready for analysis
- Metadata - Comprehensive anatomical annotations
Programmatic access enables large-scale analyses:
- Custom queries - Automated data retrieval
- Batch downloads - Large-scale analyses
- Integration - Connection to other resources like Gene Expression Omnibus (GEO)
¶ Recent Updates and Expansions
Recent years have seen major enhancements:
- Single-nucleus RNA sequencing - Cell type-specific expression data from frozen tissue
- Cell type atlas - Classification of neuronal and glial cell types
- Spatial transcriptomics - Combined spatial and transcriptional information
Comprehensive aging data:
- Gene expression in aging - Changes across the lifespan (20-100 years)
- Comparative analysis - Young vs. elderly donors
- Age-related patterns - Regional vulnerability to aging
The atlas integrates with developmental data:
- Developmental expression - From fetal to adult stages
- Temporal trajectories - Expression changes over time
- Comparative analysis - Development vs. aging trajectories
The Seattle Alzheimer's Disease Brain Cell Atlas:
- Disease-specific data - Single-nucleus data from Alzheimer's disease brains
- Cell type vulnerability - Which cells are affected in AD
- Pathological signatures - Molecular changes in disease
¶ Limitations and Considerations
Key considerations for researchers:
- Postmortem interval - Effects on RNA quality
- Aging cohort - Limited to adult brains
- Cause of death - Potential confounding factors
- Ethnic diversity - Primarily Caucasian donors
Understanding data limitations:
- Microarray vs. RNA-seq - Platform-specific biases
- Spatial resolution - Regional (not cellular) resolution for bulk data
- Normalization - Careful consideration of normalization methods
The study of Allen Human Brain Atlas has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Allen Institute for Brain Science. "Allen Human Brain Atlas." https://human.brain-map.org/
-
Hawrylycz MJ et al. (2012). "An anatomically comprehensive atlas of the adult human brain transcriptome." Nature 489: 391-399. https://doi.org/10.1038/nature11405
-
Shen EH et al. (2012). "The Allen Human Brain Atlas: a comprehensive resource for the scientific community." Brain Research 1477: 1-6.
-
Sea AD Consortium (2023). "A multimodal cell census and atlas of the mammalian primary motor cortex." Nature 622: 115-134.
-
Zeng H & Sanes JR (2017). "Neuronal cell-type classification: challenges, opportunities and the path forward." Nature Reviews Neuroscience 18: 530-546.
-
Braak H & Braak E (1991). "Neuropathological stageing of Alzheimer-related changes." Acta Neuropathologica 82: 239-259.
-
Surmeier DJ et al. (2017). "Neuronal alpha-synucleinopathy in Parkinson's disease: a singular pattern." Neuron 94: 704-718.
-
Taylor JP et al. (2016). "Amyotrophic lateral sclerosis: emerging mechanisms and therapeutic targets." The Lancet Neurology 15: 1183-1196.